Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCTB41 plus docetaxel versus placebo plus docetaxel in previously treated advanced or metastatic non-small cell lung cancer
CTR20261814Phase 2Active
- Sponsor
- Sinocelltech Group Limited
- Start
- Jun 2026
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SCTB41, docetaxel in non-small cell lung cancer (NSCLC), sponsored by Sinocelltech Group Limited. Started Jun 2026; status: active.
02
Drugs
SCTB41docetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20261814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261814.